Stocks and Investing Stocks and Investing
Wed, December 7, 2022
Tue, December 6, 2022
Mon, December 5, 2022
Sun, December 4, 2022
Fri, December 2, 2022

Alec Stranahan Downgraded (YMAB) to Hold and Decreased Target to $5 on, Dec 2nd, 2022


Published on 2024-10-28 00:25:31 - WOPRAI, Alec Stranahan
  Print publication without navigation


Alec Stranahan of B of A Securities, Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Hold and Decreased Target from $23 to $5 on, Dec 2nd, 2022.

Alec has made no other calls on YMAB in the last 4 months.



There are 6 other peers that have a rating on YMAB. Out of the 6 peers that are also analyzing YMAB, 2 agree with Alec's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022
  • David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022


These are the ratings of the 4 analyists that currently disagree with Alec


  • Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $12 on, Tuesday, November 1st, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
  • Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
  • William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022